Home LiteratureArticle Details
PMID: 8593933 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

cAMP-signaling pathway acts in selective synergism with glucose or tolbutamide to increase cytosolic Ca2+ in rat pancreatic beta-cells.

Diabetes ·Vol. 45 ·No. 3 ·1996-03-00 ·Pages 295-301

Yaekura K, Kakei M, Yada T

Abstract

cAMP and the insulinotropic peptides that raise cAMP glucose-dependently increase the cytosolic free Ca2+ concentration ([Ca2+]i) in pancreatic beta-cells, which is tightly linked to the potentiation of glucose-induced insulin release. We examined whether cAMP increases [Ca2+]i in specific cooperation only with glucose or also with other insulin secretagogues that act through different mechanisms. [Ca2+]i in single rat pancreatic beta-cells was measured by dual-wavelength fura-2 microfluorometry. In the presence of a stimulatory concentration of glucose (8.3 mmol/l) and the moderate elevation in [Ca2+]i induced by it, forskolin, an activator of adenylyl cyclase, or dibutyryl cAMP produced a marked additional increase in [Ca2+]i but was ineffective at the basal 2.8 mmol/l glucose. These cAMP-elevating agents also potentiated the effect of tolbutamide on [Ca2+]i. The cAMP-induced increase in [Ca2+]i was completely and selectively inhibited by a blocker of cAMP-dependent protein kinase A (PKA), and by nitrendipine, a blocker of the L-type Ca2+ channel. However, in the presence of high KCl and the [Ca2+]i elevation induced by it, a rise in cAMP failed to further increase [Ca2+]i, whereas BAY K8644, an agonist of L-type Ca2+ channels, evoked an additional increase in [Ca2+]i. Under low Na+ conditions, the [Ca2+]i response to cAMP was observed in the majority of the cells. In the cells in which glucose at 4.5-5 mmol/l was inadequate to increase [Ca2+]i, the glucose together with a rise in cAMP often increased [Ca2+]i. Likewise, tolbutamide and a rise in cAMP acted in concert to increase [Ca2+]i. Thus, cAMP left-shifted the concentration-[Ca2+]i response relationship for glucose and tolbutamide. In conclusion, the cAMP-PKA pathway acts in selective synergism with glucose and tolbutamide to initiate [Ca2+]i signals in pancreatic beta- cells. cAMP appears to regulate beta-cell sensitivity to glucose and tolbutamide. In contrast, cAMP fails to cooperate with high KCl to increase [Ca2+]i. It is suggested that cAMP acts mainly on a site that is more proximal but functionally linked to the L-type Ca2+ channel, thereby finally increasing Ca2+ influx through this channel.

MeSH Terms
Animals Bucladesine/pharmacology Calcium/metabolism Calcium Channel Agonists/pharmacology Calcium Channel Blockers/pharmacology Calcium Channels/metabolism Colforsin/pharmacology Cyclic AMP/metabolism,pharmacology Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors,metabolism Cytosol/metabolism Drug Synergism Enzyme Inhibitors/pharmacology Glucose/pharmacology Islets of Langerhans/metabolism Rats Rats, Wistar Signal Transduction Tolbutamide/pharmacology
Chemicals
Calcium Channel Agonists Calcium Channel Blockers Calcium Channels Enzyme Inhibitors Colforsin Bucladesine Tolbutamide Cyclic AMP Cyclic AMP-Dependent Protein Kinases Glucose Calcium
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Yaekura K
Department of Physiology, Kagoshima University School of Medicine, Japan.
Kakei M
Yada T
Article Info
Journal
Diabetes
Abbr.
Diabetes
ISSN
0012-1797
Published
1996-03-00
Pages
295-301
Language
English
Region
United States
NLM ID
0372763
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]